This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
His group then went on to apply the same technique to assess rates of gluconeogenesis in patients with poorly controlled T2D and demonstrated that virtually all of their increased glucose production can be attributed to increased rates of gluconeogenesis and that metformin lowers hepatic glucose production in these individuals by decreasing the rate of hepatic gluconeogenesis. He also demonstrated that metformin suppresses hepatic gluconeogenesis by inhibiting Complex IV and altering the cytosolic redox state. His lab developed the Positional Isotopomer NMR Tracer Analysis (PINTA) method to measure hepatic mitochondrial fluxes. With this, they showed mechanisms by which caloric restriction reverses diabetes, how leptin maintains gluconeogenesis during fasting, how the glucose-alanine cycle regulates hepatic fat oxidation, and how glucagon stimulates gluconeogenesis via the IP3R1 receptor and CaMKII. His research has also explored how adiponectin, leptin, and fibroblast growth factors (FGF-1, FGF-19, and FGF-21) regulate hepatic glucose metabolism. Contrary to the prevailing view that insulin acutely suppresses hepatic gluconeogenesis through FoxO1-mediated transcriptional repression, Shulman's team showed that suppression occurs mainly through inhibition of white adipocyte lipolysis, reducing glycerol and fatty acid flux to the liver. This leads to decreased acetyl-CoA activation of pyruvate carboxylase and lower glycerol-derived glucose production.
An OECD proposal to allocate multinational profits (for taxing purposes) to countries where they do business, by a formula, including to markets which multinationals sell into without a physical presence. This is hoped to eliminate the need for Digital Services Tax implemented by several countries, including France. There are exclusions and minimum thresholds, including banking and extractive industries. The proposal involves allocating only residual profit (i.e., profits above what is established through transfer pricing, thus creating a hybrid mechanism). This is essentially no change to what is currently allowed (routine profits allocated using transfer pricing + residual profits allocated through profit split). Pillar 2
== Clinical trials == Phase I clinical trials evaluated the safety, tolerability, and pharmacokinetics of canfosfamide. Phase II trials evaluated clinical activity in various tumor types, especially ovarian cancer and non-small cell lung cancer. Phase III trials focused on its efficacy as part of combination therapy, particularly with standard chemotherapeutic agents. However, the trials did not demonstrate significant improvement in overall survival when compared to standard treatments alone.
One can also be exposed to these hazardous drugs through injection by needle sticks. Research conducted in this area has established that occupational exposure occurs by examining evidence in multiple urine samples from health care workers.
Sources: en.wikipedia.org
==== Songs ==== "Chains" (Cookies song), 1962, covered by The Beatles "The Chain", a 1977 song by Fleetwood Mac "Chains", a song by Chicago from the 1982 album Chicago 16 "Chains" (Patty Loveless song), 1990 "Chain", a song by His Boy Elroy on their 1993 self-titled album. "Chains" (Tina Arena song), 1994 "Chains" (DLT song), 1996 "Chain", a song by the Fire Theft from their 2003 self-titled album "Chains" (Nick Jonas song), 2014 "Chains" (Usher song), 2015
Public awareness of food preservatives is uneven. Americans have a perception that food-borne illnesses happen more often in other countries. This may be true, but the occurrence of illnesses, hospitalizations, and deaths are still high. It is estimated by the Centers for Disease Control (CDC) that each year there are 76 million illnesses, 325,000 hospitalizations, and 5,000 deaths linked to food-borne illness. Food suppliers are facing difficulties with regards to the safety and quality of their products as a result of the rising demand for ready-to-eat fresh food products. Artificial preservatives meet some of these challenges by preserving freshness for longer periods of time, but these preservatives can cause negative side-effects as well.
5G cellular network – next-generation cellular networks which began deployment in 2019. Their major advantage is much higher data rates than previous cellular networks, up to 10 Gbps; 100 times faster than the previous cellular technology, 4G LTE. The higher data rates are achieved partly by using higher frequency radio waves, in the higher microwave band 3–6 GHz, and millimeter wave band, around 28 and 39 GHz. Since these frequencies have a shorter range than previous cellphone bands, the cells will be smaller than the cells in previous cellular networks which could be many miles across. Millimeter-wave cells will only be a few blocks long, and instead of a cell base station and antenna tower, they will have many small antennas attached to utility poles and buildings.
Reducing the partial pressure of the inert gas component of the breathing mixture will accelerate decompression as the concentration gradient will be greater for a given depth. This is achieved by increasing the fraction of oxygen in the breathing gas used, whereas substitution of a different inert gas will not produce the desired effect. Any substitution may introduce counter-diffusion complications, owing to differing rates of diffusion of the inert gases, which can lead to a net gain in total dissolved gas tension in a tissue. This can lead to bubble formation and growth, with decompression sickness as a consequence. Partial pressure of oxygen is usually limited to 1.6 bar during in-water decompression for scuba divers, but can be up to 1.9 bar in-water and 2.2 bar in the chamber when using the US Navy tables for surface decompression,
== Table of techniques == In the table below, ambient ionization techniques are classified in the categories "extraction" (a solid or liquid extraction processes dynamically followed by spray or chemical ionization), "plasma" (thermal or chemical desorption with chemical ionization), "two step" (desorption or ablation followed by ionization), "laser" (laser desorption or ablation followed by ionization), "acoustic" (acoustic desorption followed by ionization), multimode (involving two of the above modes), other (techniques that do not fit into the other categories).
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.